• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

tetano

Editor, Senior Moderator
Cell Rep


. 2020 Jul 3;107918.
doi: 10.1016/j.celrep.2020.107918. Online ahead of print.
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection


Jinkai Wan[SUP] 1 [/SUP], Shenghui Xing[SUP] 1 [/SUP], Longfei Ding[SUP] 2 [/SUP], Yongheng Wang[SUP] 3 [/SUP], Chenjian Gu[SUP] 4 [/SUP], Yanling Wu[SUP] 4 [/SUP], Bowen Rong[SUP] 1 [/SUP], Cheng Li[SUP] 4 [/SUP], Siqing Wang[SUP] 1 [/SUP], Kun Chen[SUP] 1 [/SUP], Chenxi He[SUP] 1 [/SUP], Dandan Zhu[SUP] 5 [/SUP], Songhua Yuan[SUP] 2 [/SUP], Chengli Qiu[SUP] 2 [/SUP], Chen Zhao[SUP] 2 [/SUP], Lei Nie[SUP] 6 [/SUP], Zhangzhao Gao[SUP] 6 [/SUP], Jingyu Jiao[SUP] 6 [/SUP], Xiaoyan Zhang[SUP] 7 [/SUP], Xiangxi Wang[SUP] 5 [/SUP], Tianlei Ying[SUP] 4 [/SUP], Haibin Wang[SUP] 6 [/SUP], Youhua Xie[SUP] 8 [/SUP], Yanan Lu[SUP] 9 [/SUP], Jianqing Xu[SUP] 10 [/SUP], Fei Lan[SUP] 11 [/SUP]



Affiliations

Abstract

Coronavirus disease 2019 (COVID-19) has become a worldwide threat to humans, and neutralizing antibodies have therapeutic potential. We have purified more than 1,000 memory B cells specific to SARS-CoV-2 S1 or its RBD (receptor binding domain) and obtain 729 paired heavy- and light-chain fragments. Among these, 178 antibodies test positive for antigen binding, and the majority of the top 17 binders with EC[SUB]50[/SUB] below 1 nM are RBD binders. Furthermore, we identify 11 neutralizing antibodies, eight of which show IC[SUB]50[/SUB] within 10 nM, and the best one, 414-1, with IC[SUB]50[/SUB] of 1.75 nM. Through epitope mapping, we find three main epitopes in RBD recognized by these antibodies, and epitope-B antibody 553-15 could substantially enhance the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross neutralize the SARS-CoV pseudovirus. Altogether, our study provides 11 potent human neutralizing antibodies for COVID-19 as therapeutic candidates.

Keywords: COVID-19; RBD; SARS-CoV-2; coronavirus; cross-neutralizing antibody; epitope; human antibodies; infection; neutralizing antibodies; spike protein.
 
Back
Top Bottom